Aspirin Resistance Following Coronary Bypass Surgery - Full Text View

Sponsored by:	Sheba Medical Center
Information provided by:	Sheba Medical Center
ClinicalTrials.gov Identifier:	NCT00260377

Purpose

Aspirin was proved to be the drug preventing vein grafts from closure and improving clinical outcome after coronary artery bypass surgery. It appears to be effective when being prescribed as early as first 48 hr. after the operation without increasing the incidence of bleeding complications. the exact effective dose is not known.

Condition	Intervention
Ischemic Heart Disease	Procedure: Coronary artery bypass surgery

MedlinePlus related topics: Coronary Artery Bypass Surgery Heart Diseases

Drug Information available for: Acetylsalicylic acid

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment

Further study details as provided by Sheba Medical Center:

Primary Outcome Measures:

Ventilation
Inotropic support
Mortality
Perioperative MI
Perioperative stroke
Bleeding / reopen / transfusion
Dysrhythmias

Secondary Outcome Measures:

ICU stay
In-hospital stay
Non-fatal cardiac events - MI, recurrence of angina, dysrhythmias
Need for repeat revascularization

Study Start Date:	January 2005
Estimated Study Completion Date:	December 2006
Estimated Primary Completion Date:	June 2006 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	30 Years to 90 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients undergoing Coronary artery bypass surgery
Patients who signed Informed Consent Form

Exclusion Criteria:

Concomitant valve surgery or carotid surgery or off-pump surgery
Need for anticoagulation therapy for any reason
Another antiplatelet medications at least 7 days prior to surgery
Contra-indication for aspirin treatment
Thrombocytopenia / thrombocytopathia
NSAIDs treatment for chronic medical conditions
Reluctance to participate in the study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00260377

Locations

Israel
Sheba Medical Center
Ramat-Gan, Israel

Sponsors and Collaborators

Sheba Medical Center

Investigators

Principal Investigator:

Jacob Lavee, Dr

jacob.lavee@sheba.health.gov.il

More Information

Study ID Numbers:	SHEBA-03-3107-JL-CTIL
Study First Received:	November 29, 2005
Last Updated:	September 8, 2008
ClinicalTrials.gov Identifier:	NCT00260377
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Sheba Medical Center:

Aspirin treatment
Aspirin resistance
Coronary bypass surgery

Study placed in the following topic categories:

Heart Diseases
Aspirin
Myocardial Ischemia
Vascular Diseases
Ischemia

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 14, 2009